Axsome Therapeutics announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for AXS-07, an investigational medicine for the acute treatment of migraine. The FDA has designated the resubmission as a Class 2 resubmission and assigned a Prescription Drug User Fee Act (PDUFA) action goal date of January 31, 2025.
AXS-07: A Novel Approach to Migraine Relief
AXS-07 is an oral, rapidly absorbed, multi-mechanistic drug comprised of MoSEIC™ meloxicam and rizatriptan. Meloxicam, a COX-2 preferential non-steroidal anti-inflammatory drug (NSAID), is formulated with Axsome’s MoSEIC (Molecular Solubility Enhanced Inclusion Complex) technology to enhance its absorption while maintaining a long plasma half-life. Rizatriptan is a 5-HT1B/1D agonist. The combination is designed to provide rapid, enhanced, and consistent relief of migraine symptoms, with reduced recurrence.
The Burden of Migraine
Migraine is a debilitating neurological condition characterized by recurrent attacks of severe head pain, often accompanied by nausea, light sensitivity, and sound sensitivity. According to the American Migraine Foundation, it affects an estimated 39 million Americans and is the leading cause of disability among neurological disorders in the United States. Surveys indicate that over 70% of migraine sufferers are not fully satisfied with their current treatments, expressing a need for therapies that offer faster, more consistent relief and reduce symptom recurrence.
Addressing Unmet Needs in Migraine Treatment
AXS-07 aims to address these unmet needs by providing a rapidly absorbed and multi-mechanistic approach to migraine relief. The combination of meloxicam and rizatriptan targets different pathways involved in migraine pathophysiology, potentially leading to more effective and consistent outcomes. With over 200 issued U.S. and international patents providing protection until at least 2038, AXS-07 represents a significant advancement in migraine therapy if approved.
